Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Medtronic
Chubb
McKinsey
McKesson
Cipla

Generated: August 22, 2019

DrugPatentWatch Database Preview

Patent: 7,795,033

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,795,033
Title:Methods to predict the outcome of treatment with antidepressant medication
Abstract: The invention provides a method for determining the outcome of treatment with an antidepressant medication in a patient. In particular, the invention provides a method of screening patients to identify those patients with a decreased risk of non-response to treatment with antidepressant medication by obtaining a sample of genetic material from the patients, and then assaying the sample for the presence of a genotype which is associated with a decreased risk of non-response to treatment with antidepressant medication. The genotype is characterized by a polymorphism in the genes HTR2A, GRIK4, BCL2, and a combination thereof.
Inventor(s): McMahon; Francis J. (Bethesda, MD), Laje; Gonzalo E. (Potomac, MD), Paddock; Silvia (Solna, SE), Manji; Husseini K. (Titusville, NJ), Rush; A. John (Singapore, SG), Wilson; Alexander F. (Phoenix, MD)
Assignee: The United States of America as represented by the Department of Health and Human Services (Washington, DC) N/A (Austin, TX) Board of Regents, The University of Texas System (N/A)
Application Number:12/051,494
Patent Claims:see list of patent claims

Details for Patent 7,795,033

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ➤ Sign Up The United States of America as represented by the Department of Health and Human Services (Washington, DC) N/A (Austin, TX) Board of Regents, The University of Texas System (N/A) 2027-03-19 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ➤ Sign Up The United States of America as represented by the Department of Health and Human Services (Washington, DC) N/A (Austin, TX) Board of Regents, The University of Texas System (N/A) 2027-03-19 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ➤ Sign Up The United States of America as represented by the Department of Health and Human Services (Washington, DC) N/A (Austin, TX) Board of Regents, The University of Texas System (N/A) 2027-03-19 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Medtronic
Covington
US Army
McKinsey
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.